CA Patent

CA2890346A1 — Novel fusion molecules and uses thereof

Assigned to Foundation Medicine Inc · Expires 2014-05-08 · 12y expired

What this patent protects

Novel fusion molecules and uses are disclosed.

USPTO Abstract

Novel fusion molecules and uses are disclosed.

Drugs covered by this patent

larotrectinib-sulfate (LAROTRECTINIB SULFATE)

Patent Metadata

Patent number: CA2890346A1
Jurisdiction: CA
Classification: —
Expires: 2014-05-08
Drug substance claim: No
Drug product claim: No
Assignee: Foundation Medicine Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.